Description
Olaparib is a potent oral PARP inhibitor used to treat BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. By blocking DNA repair in cancer cells, it induces synthetic lethality, selectively targeting tumor cells and significantly improving progression-free survival in advanced malignancies.